Melatonin supplementation in multiple sclerosis: a systematic review of clinical, imaging, biomarker, and safety outcomes
Authors:
Open Access
- 25 September 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1889519
Abstract
Purpose: Melatonin may act on immune, oxidative, and circadian pathways relevant to multiple sclerosis (MS), yet its clinical benefits and safety profile remain unclear. This systematic review assessed the efficacy and safety of oral melatonin supplementation in adults with MS. Methods: We searched MEDLINE (via PubMed), Scopus, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception through August 15, 2026, and included randomized and prospective non-randomized intervention studies. Two reviewers independently selected studies, extracted data, and assessed risk of bias using RoB 2 or ROBINS-I. Given substantial clinical and methodological heterogeneity, we synthesized findings without meta-analysis, following SWiM guidance, and rated certainty of evidence with GRADE. We registered the protocol in PROSPERO (CRD420251167112). Results: We included 10 independent studies, reported across 17 publications, covering 435 participants. Nine were randomized trials (two of them crossover designs), and one was a prospective non-randomized intervention study. Melatonin doses spanned 0.5–300 mg/day, with treatment durations from 2 weeks to 14 months. The evidence did not show reductions in relapse activity, disability progression, or new MRI activity. Small studies suggested possible improvements in sleep, fatigue, pain, physical function, cognition, mood, autonomic function, body composition, and inflammatory, metabolic, or oxidative-stress biomarkers, but these results were inconsistent and rarely replicated. Doses of 0.5–25 mg/day were generally well tolerated, though some participants discontinued treatment and adverse-event reporting remained incomplete. At 300 mg/day, three of four melatonin-treated participants developed hypertransaminasemia, which resolved after withdrawal and recurred on rechallenge in one case. Certainty of evidence was low or very low for every outcome assessed. Conclusion: Current evidence does not support a disease-modifying effect of melatonin in MS. Any symptomatic or biomarker benefits need confirmation in larger, well-designed trials, and high-dose melatonin may carry meaningful hepatic risk.Keywords
This publication has 32 references indexed in Scilit:
- Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1)CNS Drugs, 2026
- Melatonin ameliorates astrogliosis and microgliosis in a cuprizone demyelinating mouse modelBiochemistry and Biophysics Reports, 2025
- 12-week melatonin intake attenuates cardiac autonomic dysfunction and oxidative stress in multiple sclerosis patients: a randomized controlled trialMetabolic Brain Disease, 2024
- 12-week melatonin supplementation improved dynamic postural stability and walking performance in persons living with multiple sclerosis: A randomized controlled trialBehavioural Brain Research, 2024
- Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic reviewInflammopharmacology, 2023
- Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple SclerosisJournal of Molecular Neuroscience, 2019
- Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple SclerosisArchives of Medical Research, 2018
- Anti‐inflammatory effects of melatonin in multiple sclerosisBioEssays, 2016
- Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balanceBrain, Behavior, and Immunity, 2015
- Melatonin Acts as Antioxidant and Improves Sleep in MS PatientsNeurochemical Research, 2014